Timed OSKM Expression Aligns with Circadian Chromatin Opening to Enhance Reprogramming Efficiency

Hypothesis

Expressing OSKM factors during the circadian window when CLOCK‑BMAL1 heterodimers peak chromatin accessibility will significantly increase the efficiency of epigenetic rejuvenation compared to constitutive or mistimed expression.

Mechanistic Rationale

• Cyclic OSKM reverses multiple hallmarks of aging and improves organ function in aged mice【https://doi.org/10.1016/j.cell.2016.11.052】.
• Aged astrocytes and microglia lose rhythmic expression of core clock genes such as Arntl/BMAL1 and Per2, indicating circadian decay in glial populations【https://doi.org/10.1101/2024.06.16.599193】.
• CLOCK protein physically stabilizes heterochromatin in mesenchymal stem cells, linking the clock to chromatin state【https://doi.org/10.1038/s41422-020-0385-7】.
• Restoring Bmal1 in muscle alone extends lifespan and improves systemic health, showing that circadian machinery can drive rejuvenation【https://insight.jci.org/articles/view/174007】.

From these data we infer that CLOCK‑BMAL1 activity gates chromatin openness. When CLOCK‑BMAL1 binds E‑box elements, it recruits histone acetyltransferases and reduces heterochromatin density, creating a permissive window for transcription factor access. If OSKM factors require transient chromatin loosening to reset DNA methylation and histone marks, then delivering them in phase with peak CLOCK‑BMAL1 activity should lower the energetic barrier for reprogramming.

Experimental Design

1. Mouse model: Use aged (≥20 mo) C57BL/6J mice carrying a doxycycline‑inducible OSKM cassette (Rosa26‑LSL‑OSKM) and a tamoxifen‑inducible CreERT2 driven by a ubiquitous promoter (CAG‑CreERT2).
2. Circadian monitoring: Implant bioluminescent reporters (Per2‑Luc) in subcutaneous tissue to determine individual circadian phase in vivo.
3. Intervention groups:
   • Group A (ZT0‑6): OSKM induced for 4 h daily at circadian time 0‑6 (subjective day, when CLOCK‑BMAL1 activity is low).
   • Group B (ZT12‑18): OSKM induced for 4 h daily at circadian time 12‑18 (subjective night, when CLOCK‑BMAL1 activity peaks).
   • Group C (Constitutive): Continuous low‑dox OSKM expression (control from original reprogramming studies).
   • Group D (Vehicle): No OSKM induction.
4. Readouts (after 4 weeks):
   • Epigenetic age via blood DNA methylation clock (Horvath mouse).
   • Heterochromatin marks (H3K9me3, HP1α) in liver and muscle by immunofluorescence and ATAC‑seq to assess chromatin accessibility.
   • Expression of core clock genes (Bmal1, Per2) in target tissues.
   • Functional assays: grip strength, treadmill endurance, glucose tolerance.
5. Sample size: n = 10 per group, powered to detect a 15 % difference in epigenetic age acceleration (α = 0.05, β = 0.8).

Predicted Outcomes

• Group B (OSKM aligned with peak CLOCK‑BMAL1) will show the greatest reduction in epigenetic age, highest increase in chromatin accessibility at OSKM target loci, and strongest improvement in physiological endpoints.
• Group A will exhibit modest or no benefit relative to Group C, indicating that mistimed delivery diminishes reprogramming efficiency.
• If the hypothesis is false, all OSKM groups will display similar rejuvenation regardless of timing, suggesting circadian chromatin state is not a limiting factor.

Potential Caveats and Alternatives

• Individual variability in circadian phase could blur group effects; using Per2‑Luc reporters to personalize dosing timing may mitigate this.
• Chronic OSKM expression may trigger adverse effects ( tumorigenesis); limiting induction to short daily pulses reduces risk.
• Other circadian regulators (e.g., REV‑ERBα) might independently influence chromatin; parallel knockdown experiments could dissect specificity.

This framework directly tests whether the circadian clock acts as a permissive gate for epigenetic reprogramming, moving beyond correlation to establish a causal, mechanistic link between temporal chromatin dynamics and aging reversal.